CEO and Co-Founder Oriana Papin-Zoghbi selected for the TITAN 100 list, recognizing the top 100 CEOs & C-level executives in Colorado
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the TITAN 100 list. The list highlights Colorado’s most accomplished business leaders in their industry.
AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer with early detection and high accuracy, and to expand their GlycoLocate™ Platform to target a broader range of cancers
AOA Dx is announcing an oversubscribed $17 million round led by Good Growth Capital with participation from leading investors including RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund. Several funds invested for the second time, underpinning the continuous success of AOA Dx across the last year.
CEO and Co-Founder Oriana Papin-Zoghbi selected for Bloomberg New Economy Catalysts
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the Bloomberg New Economy Catalysts and will represent the women’s health industry at the Bloomberg New Economy Forum in Singapore.
AOA Dx’s First Peer Reviewed Study Accepted for Publication in Prestigious Journal Frontiers in Oncology
AOA Dx, a biotech company developing a new frontier in early-stage cancer detection through its work in glycolipids, is proud to announce the company’s first published peer reviewed clinical study.
AOA Dx Announces First Patient Enrolled in OVERT Clinical Study Evaluating the AKRIVIS GD™ test for Early Detection of Ovarian Cancer
AOA Dx today announced that the first patient has been enrolled in their OVERT (Ovarian Cancer Early Detection Research) clinical trial. The OVERT trial is a multi-center national trial, the first of its kind in a symptomatic U.S. population. AOA Dx is working with world renowned clinicians and healthcare institutions across the US to bring to market the first test for the early detection of ovarian cancer.
AOA Dx Announces Initial Validation of Novel Tumor Gangliosides as Promising Diagnostic Markers for Early Detection of Ovarian Cancer
AOA Dx announces initial validation of GD2 and GD3 tumor marker gangliosides as novel diagnostic markers for early detection of ovarian cancer. AOA Dx results will be presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Massachusetts Innovation Network Announces AOA Dx as the Award Recipient of Three Awards at The Eddies
AOA Dx is proud to announce the company has won the Life Science award, the People’s Choice Award, and the Robert J. Crowley award at the Massachusetts Innovation Network’ signature innovation competition, The Eddies. The Robert J. Crowley award honors those embodying the values of breakthrough thinking, passion to improve lives and unwavering commitment to the spirit of advancement.
AOA Dx Co-Founders Oriana Papin-Zoghbi and Anna Jeter Named to Inc.’s 2022 Female Founders 100 List
AOA Dx is proud to announce that co-founders Oriana Papin-Zoghbi and Anna Jeter have been named to Inc.’s 2022 Female Founders 100 List.
Inc.’s fifth annual Female Founders 100 list honors a bold group of 100 women whose innovations and ideas are shaping the world into a better place. Collectively, the 2022 honorees’ companies are estimated to be worth more than $22 billion.
AOA Dx Closes $7 million Funding Round to Bring the First Accurate Early Detection Test for Ovarian Cancer to Market
AOA Dx Inc is proud to announce that they have closed both of their seed rounds totaling a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent and other notable investors.
The funding will be used to further develop the next generation of AOA’s ovarian cancer detection technology, AKRIVIS GD™ and expand their growing team. Currently, there are no reliable ovarian cancer biomarkers that detect early stage disease.
AOA Dx was selected for MassChallenge’s 2022 US Early-Stage Cohort
AOA Dx is excited to share that the company has been selected to participate in the MassChallenge 2022 accelerator program, joining more than 200 startups. AOA Dx was one of over 1,000 other startup applications for this year’s program.